JP2010506939A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010506939A5 JP2010506939A5 JP2009533405A JP2009533405A JP2010506939A5 JP 2010506939 A5 JP2010506939 A5 JP 2010506939A5 JP 2009533405 A JP2009533405 A JP 2009533405A JP 2009533405 A JP2009533405 A JP 2009533405A JP 2010506939 A5 JP2010506939 A5 JP 2010506939A5
- Authority
- JP
- Japan
- Prior art keywords
- dna
- pathway
- repair
- inhibitor
- dna repair
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85320806P | 2006-10-20 | 2006-10-20 | |
| US89560607P | 2007-03-19 | 2007-03-19 | |
| PCT/US2007/022439 WO2008066624A2 (en) | 2006-10-20 | 2007-10-22 | Dna damage repair inhibitors and methods for treating cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010506939A JP2010506939A (ja) | 2010-03-04 |
| JP2010506939A5 true JP2010506939A5 (https=) | 2012-01-05 |
Family
ID=39327045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009533405A Withdrawn JP2010506939A (ja) | 2006-10-20 | 2007-10-22 | ガンを処置するためのｄｎａ損傷修復阻害剤および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20090062196A1 (https=) |
| EP (1) | EP2092083A2 (https=) |
| JP (1) | JP2010506939A (https=) |
| AU (1) | AU2007325900A1 (https=) |
| CA (1) | CA2703006A1 (https=) |
| WO (1) | WO2008066624A2 (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2092083A2 (en) | 2006-10-20 | 2009-08-26 | Dana-Farber Cancer Institute | Dna damage repair inhibitors and methods for treating cancer |
| GB0713192D0 (en) * | 2007-07-06 | 2007-08-15 | Vereniging Het Nl Kanker I | Anti-tumour methods |
| US20110028338A1 (en) | 2008-04-02 | 2011-02-03 | John Chute | Signatures of radiation response |
| EP2297345A1 (en) * | 2008-05-14 | 2011-03-23 | DNAR, Inc | Biomarkers for the identification, monitoring, and treatment of head and neck cancer |
| WO2009144154A1 (en) * | 2008-05-30 | 2009-12-03 | Pangaea Biotech, S.A. | Methods and reagents for predicting clinical outcome and customizing chemotherapy in lung cancer patients |
| CN102203295A (zh) * | 2008-09-03 | 2011-09-28 | 约翰霍普金斯大学 | 胰腺肿瘤发生的通路及遗传性胰腺癌基因 |
| WO2010089707A1 (en) * | 2009-02-04 | 2010-08-12 | Yeda Research And Development Co. Ltd. | Methods and kits for determining sensitivity or resistance of prostate cancer to radiation therapy |
| GB2471065A (en) * | 2009-06-10 | 2010-12-22 | Univ Sheffield | Modulator of claspin for treatment of cell proliferative disorder |
| EP2457095A1 (en) * | 2009-07-24 | 2012-05-30 | Institut Gustave Roussy | Parp and adjuvant cisplatin-based chemotherapy in non-small-cell lung cancer |
| CA2797719C (en) * | 2010-04-30 | 2019-11-26 | Dana-Farber Cancer Institute, Inc. | Small molecule inhibitors of usp1 deubiquitinating enzyme activity |
| WO2011143337A1 (en) * | 2010-05-11 | 2011-11-17 | On-Q-ity | Biomarkers for the identification monitoring and treatment of breast cancer |
| GB201011367D0 (en) * | 2010-07-06 | 2010-08-18 | Medical Res Council | Methods |
| EP2619574B1 (en) | 2010-09-15 | 2020-10-28 | Almac Diagnostic Services Limited | Molecular test for predicting responsiveness to dna-damage therapeutic agents in individuals having cancer |
| CA2742342A1 (en) * | 2011-02-12 | 2012-08-12 | Baylor Research Institute | Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs |
| JP5762103B2 (ja) * | 2011-04-13 | 2015-08-12 | 国立大学法人滋賀医科大学 | 頭頸部癌及び食道癌用抗癌剤及び増強剤 |
| CN103890195A (zh) * | 2011-09-08 | 2014-06-25 | 耶达研究及发展有限公司 | 用于肺癌的新型风险生物标志物 |
| US8729048B2 (en) | 2011-11-22 | 2014-05-20 | Mayo Foundation For Medical Education And Research | Methods and materials for assessing responsiveness to PARP inhibitors and platinating agents |
| WO2013184905A1 (en) | 2012-06-06 | 2013-12-12 | Myriad Genetics, Inc. | Hereditary cancer genes |
| US10370712B2 (en) | 2012-09-24 | 2019-08-06 | Duke University | Signatures of radiation response |
| EP3052655B1 (en) | 2013-09-30 | 2018-11-07 | Institute For Cancer Research D/b/a The Research Institute of Fox Chase Cancer Center | Closantel in combination with temozolomide for use in the treatment of a cancer in which is thymine dna glycosylase expressed |
| WO2015118338A1 (en) * | 2014-02-07 | 2015-08-13 | Mission Therapeutics Limited | Methods for exploiting synthetic lethality and chemo-sensitisation in dna damage response (ddr) pathways |
| US9725425B1 (en) | 2014-02-25 | 2017-08-08 | Dana-Farber Cancer Institute, Inc. | Compounds and methods for treating cancer |
| US20150344968A1 (en) * | 2014-05-30 | 2015-12-03 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Methods for determining parp inhibitor and platinum resistance in cancer therapy |
| EP3172338B1 (en) | 2014-07-25 | 2018-10-31 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods for predicting response to dna repair pathway inhibitors in diffuse large b-cell lymphoma |
| WO2016078660A1 (en) * | 2014-11-20 | 2016-05-26 | Københavns Universitet | Detecting replication catastrophe in cells |
| US20210275630A1 (en) * | 2016-04-18 | 2021-09-09 | Phoremost Limited | Inactivation of dna repair as an anticancer therapy |
| JP7224185B2 (ja) | 2016-05-01 | 2023-02-17 | ゲノム・リサーチ・リミテッド | Ｄｎａサンプルを特徴付ける方法 |
| EP3452937B1 (en) | 2016-05-01 | 2025-10-22 | Genome Research Limited | Method of characterising a dna sample |
| CA3051590A1 (en) * | 2017-01-25 | 2018-08-02 | Indiana University Research And Technology Corporation | Prophylaxis and treatment of acute myeloid leukemia |
| CN107190007B (zh) * | 2017-07-11 | 2021-02-23 | 信雅生物科技（苏州）有限公司 | 一种特异性敲减人brcc3基因慢病毒的构建及在肺癌中的应用 |
| EP3700538A4 (en) | 2017-10-23 | 2020-12-02 | Mark David Vincent | METHODS OF TREATING CANCER AND / OR IMPROVING SUSCEPTIBILITY TO CANCER TREATMENT BY INCREASING THE BURDEN OF TUMOR MUTATIONS OR TUMOR INDELS |
| US11413288B2 (en) * | 2017-11-01 | 2022-08-16 | Dana-Farber Cancer Institute, Inc. | Methods of treating cancers |
| EP3502700A1 (en) * | 2017-12-21 | 2019-06-26 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Methods based on the detection of rad51 foci in tumor cells |
| US11485736B2 (en) | 2018-12-20 | 2022-11-01 | KSQ Therapeutics, Inc. | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors |
| EP4516300A3 (en) * | 2019-06-14 | 2025-08-06 | Children's Hospital Medical Center | Rational therapeutic targeting of oncogenic immune signaling states in myeloid malignancies via the ubiquitin conjugating enzyme ube2n |
| EP4006527B1 (en) | 2019-07-25 | 2025-07-16 | Seoul Viosys Co., Ltd | Light irradiation apparatus comprising led and method of using the same |
| WO2021209517A1 (en) | 2020-04-15 | 2021-10-21 | Centre National De La Recherche Scientifique | Prognosis method of acute myeloid leukaemia |
| KR20230098186A (ko) | 2020-10-30 | 2023-07-03 | 케이에스큐 세러퓨틱스 인코포레이티드 | 치환된 피라졸로피리미딘의 고체 상태 형태 및 이의 용도 |
| GB202113610D0 (en) * | 2021-09-23 | 2021-11-10 | Francis Crick Institute Ltd | Novel method |
| CN120741580B (zh) * | 2025-06-27 | 2026-03-20 | 江苏香地化学有限公司 | 一种用于检测丝裂霉素c的分子印迹比率型工作电极及其制备方法和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2000280389A1 (en) * | 2001-11-02 | 2003-05-19 | Dana-Farber Cancer Institute | Methods and compositions for the diagnosis of cancer susceptibilities and defective dna repair mechanisms and treatment thereof |
| GB0317466D0 (en) * | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
| US8227434B1 (en) * | 2003-11-04 | 2012-07-24 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Materials and methods for treating oncological disorders |
| PL2305221T3 (pl) * | 2003-12-01 | 2015-11-30 | Kudos Pharm Ltd | Inhibitory naprawy uszkodzeń DNA w leczeniu raka |
| CA2609751A1 (en) * | 2005-05-24 | 2006-11-30 | Dana Farber Cancer Institute, Inc. | Compositions and methods for the treatment of cancer |
| EP2092083A2 (en) | 2006-10-20 | 2009-08-26 | Dana-Farber Cancer Institute | Dna damage repair inhibitors and methods for treating cancer |
-
2007
- 2007-10-22 EP EP07867262A patent/EP2092083A2/en not_active Withdrawn
- 2007-10-22 US US11/975,997 patent/US20090062196A1/en not_active Abandoned
- 2007-10-22 JP JP2009533405A patent/JP2010506939A/ja not_active Withdrawn
- 2007-10-22 AU AU2007325900A patent/AU2007325900A1/en not_active Abandoned
- 2007-10-22 WO PCT/US2007/022439 patent/WO2008066624A2/en not_active Ceased
- 2007-10-22 CA CA2703006A patent/CA2703006A1/en not_active Abandoned
-
2015
- 2015-11-23 US US14/948,914 patent/US10738310B2/en active Active
-
2019
- 2019-08-12 US US16/537,899 patent/US20200140868A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010506939A5 (https=) | ||
| Frick et al. | Overt increase of oxidative stress and DNA damage in murine and human colitis and colitis-associated neoplasia | |
| Stover et al. | Biomarkers of response and resistance to DNA repair targeted therapies | |
| Xia et al. | A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance | |
| Du et al. | Histone modification-dependent and-independent pathways for recruitment of checkpoint protein Crb2 to double-strand breaks | |
| JP6016792B2 (ja) | ナノポア促進型の核酸の単分子検出 | |
| ES2742285T3 (es) | Marcadores asociados con la sensibilidad a inhibidores del doble minuto humano 2 (MDM2) | |
| Litwin et al. | Oxidative stress and replication-independent DNA breakage induced by arsenic in Saccharomyces cerevisiae | |
| US10449202B2 (en) | Rationale-based design of a targeted therapy for cancer | |
| Kanellis et al. | A screen for suppressors of gross chromosomal rearrangements identifies a conserved role for PLP in preventing DNA lesions | |
| US20180140578A1 (en) | Methods and compositions for the diagnosis and selective treatment of cancer | |
| Olewinska et al. | Level of DNA damage in lead-exposed workers | |
| Kumari et al. | p53 protects from replication-associated DNA double-strand breaks in mammalian cells | |
| E. Hardie et al. | Cisplatin analogues with an increased interaction with DNA: Prospects for therapy | |
| US20220275460A1 (en) | Molecular predictors of patient response to radiotherapy treatment | |
| Chang et al. | Fast simultaneous detection of K-RAS mutations in colorectal cancer | |
| CN102186990A (zh) | Dna的定量或检测方法 | |
| CN106662543A (zh) | 肺癌患者中的非侵入性基因突变检测 | |
| JP2024508895A5 (https=) | ||
| Tembe et al. | Open-access synthetic spike-in mRNA-seq data for cancer gene fusions | |
| CN110863035A (zh) | 一种检测dna直接修复通路有效性的探针库、检测方法和试剂盒 | |
| US11479764B2 (en) | Method and kit for concentrating target double-stranded nucleic acid molecules using a pyrrole-imidazole-containing polyamide | |
| Kim et al. | hMLH1 promoter methylation and BRAF mutations in high-frequency microsatellite instability colorectal cancers not fulfilling the revised Bethesda guidelines | |
| Li et al. | Panel sequencing of 264 candidate susceptibility genes and segregation analysis in a cohort of non-BRCA1, non-BRCA2 breast cancer families | |
| Skopelitou et al. | Whole exome sequencing identifies novel germline variants of SLC15A4 gene as potentially cancer predisposing in familial colorectal cancer |